

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Chun Li et al.

Title: WATER SOLUBLE PACLITAXEL DERIVATIVES

Appl. No.: Unassigned

Filing Date: 4/19/04

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/300,031, filed 11/20/2002. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

The relevance of the documents is explained in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 19 April 2004

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicants
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 19, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned
				Filing Date	4/19/04
				First Named Inventor	Chun Li
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	077319-0406

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	US005473055	A	Mongeli et al.	12/1995	
	A2	US005846565	A	Brem et al.	12/1998	
	A3	US006127355	A	Greenwald et al.	10/2000	
	A4	US006218367	B	Jacob	04/2001	
	A5	US006262107	B	Li et al.	07/2001	
	A6	5,473,055	A	Mongelli et al.	12/1995	
	A7	5,626,862		Brem et al.	05/1997	
	A8	5,730,968		Butterfield et al.	03/1998	
	A9	5,776,925		Young et al.	07/1998	
	A10	5,846,565	A	Brem et al. (II)	12/1998	
	A11	6,127,355	A	Greenwald et al.	10/2000	
	A12	6,218,367	B	Jacob	04/2001	
	A13	6,262,107	B	Li et al.	07/2001	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A14	Li et al., "Enhancement of Tumor Radioresponse of A Murine Ovarian Carcinoma By Poly(L-Glutamic Acid)-Paclitaxel Conjugate", <i>CTI 9th Annual International Symposium on Recent Advances in Drug Delivery Systems</i> , February 22-25, 1999, (2 pages).	
	A15	Ke et al., "Schedule-Independent Radiosensitization of a Murine Ovarian Oca-1 Tumor by PG-TXL", <i>CTI Proceedings of the American Association for Cancer Research</i> , Vol 40, # 4223, Ref. 248, March 1999 (1 page).	
	A16	Li et al., "Water-Soluble Polyglutamic Acid-Paclitaxel Conjugate (PGA-Paclitaxel): Antitumor Regression in Rats Braeing 13762 Mammary Carcinoma", <i>Pharmaceutical Research</i> , September 1996, Vol. 13, Number 9, page S-368, Abstract PDD 7541, see entire abstract.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.